Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study
Neurological Sciences · 2025
DOI: 10.1007/s10072-024-07819-8 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Neurological Sciences, 2025. Verfasst von Zhuajin Bi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Tacrolimus, Myasthenia Gravis, Immunosuppressive Agents, Receptors, Cholinergic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the long-term efficacy and safety of tacrolimus in patients with muscle-specific kinase antibody-positive myasthenia gravis (MuSK-MG). METHODS: We performed a retrospective, single-center, and cross-sectional study analyzing medical records of 18 MuSK-MG patients treated with tacrolimus for more than 1 year. The efficacy and safety of tacrolimus were evaluated by modified Osserman scale, Myasthenia Gravis Foundation of America post-intervention status, prednisone dosage, quantitative MG (QMG) scores, MG-activity of daily living (MG-ADL) scores, anti-MuSK antibody titers, blood routine, and serum biochemicals. RESULTS: After 4 weeks of tacrolimus treatment, there was a significant improvement in prednisone dose, QMG, and MG-ADL scores, which continued to improve over 1 year. In addition, clinical grade of modified Osserman scale was improved in all patients, 16 (88.9%) of whom were asymptomatic at the last visit. More importantly, the mean titers of anti-MuSK antibody were significantly decreased from 0.777 ± 0.381 to 0.283 ± 0.178 nmol/L after a median of 1.4 years of tacrolimus treatment in 9 patients with MuSK-MG (P = 0.015). All patients achieved minimal manifestations status (MMS) after tacrolimus treatment (range, 4-32 weeks). Subsequently, seven patients (38.9%) underwent a taper of tacrolimus dosage. However, four patients (57.1%) experienced an exacerbation. Adverse events occurred in 2 patients (11.1%), all of which were mild and resolved after the tacrolimus dose was adjusted or discontinued. CONCLUSION: Our results suggest that tacrolimus may be an effective and safe steroid-sparing treatment for patients with MuSK-MG. However, tacrolimus should be carefully tapered to avoid disease exacerbation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei Province, China.
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei Province, China. lizhijun@tjh.tjmu.edu.cn.
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei Province, China. bubitao@tjh.tjmu.edu.cn.
Zitieren
APA
Bi, Z., Li, Y., Lin, J., Gui, M., Li, Z., & Bu, B. (2025). Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study. Neurological Sciences. https://doi.org/10.1007/s10072-024-07819-8
Vancouver
Bi Z, Li Y, Lin J, Gui M, Li Z, Bu B. Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study. Neurological Sciences. 2025. doi:10.1007/s10072-024-07819-8
BibTeX
@article{Bi2025,
author = {Bi, Zhuajin and Li, Yue and Lin, Jing and Gui, Mengcui and Li, Zhijun and Bu, Bitao},
title = {Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-024-07819-8}
}
EUVIMED